BR112015006642A2 - metadoxina, composição farmacêutica e composição farmacêutica de liberação prolongada - Google Patents

metadoxina, composição farmacêutica e composição farmacêutica de liberação prolongada

Info

Publication number
BR112015006642A2
BR112015006642A2 BR112015006642A BR112015006642A BR112015006642A2 BR 112015006642 A2 BR112015006642 A2 BR 112015006642A2 BR 112015006642 A BR112015006642 A BR 112015006642A BR 112015006642 A BR112015006642 A BR 112015006642A BR 112015006642 A2 BR112015006642 A2 BR 112015006642A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
metadoxine
extended release
release pharmaceutical
alcoholic
Prior art date
Application number
BR112015006642A
Other languages
English (en)
Other versions
BR112015006642B1 (pt
Inventor
Van Gulik Frederick
Bodapunti Prabha Shankar
Madhududan Rao Yamsani
Original Assignee
Eurodrug Laboratories B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurodrug Laboratories B V filed Critical Eurodrug Laboratories B V
Publication of BR112015006642A2 publication Critical patent/BR112015006642A2/pt
Publication of BR112015006642B1 publication Critical patent/BR112015006642B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo “metadoxina, composição farmacêutica e composição farmacêutica de liberação prolongada” a invenção se refere ao uso de metadoxina na prevenção e no tratamento de doença de gordura no fígado não-alcóolica (naflc) e esteatohepatite não-alcóolica (nash), na melhora de taxa de sobrevivência de pacientes com varias hepatite alcóolica e para novas formulações farmacêuticas de liberação prolongada compreendendo metadoxina.
BR112015006642-9A 2012-09-26 2013-01-22 Composição farmacêutica de liberação prolongada compreendendo metadoxina e prednisona BR112015006642B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2012004028 2012-09-26
EP2012/004028 2012-09-26
PCT/EP2013/000183 WO2014048511A1 (en) 2012-09-26 2013-01-22 Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations

Publications (2)

Publication Number Publication Date
BR112015006642A2 true BR112015006642A2 (pt) 2017-07-04
BR112015006642B1 BR112015006642B1 (pt) 2022-08-02

Family

ID=47018954

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015006642-9A BR112015006642B1 (pt) 2012-09-26 2013-01-22 Composição farmacêutica de liberação prolongada compreendendo metadoxina e prednisona

Country Status (6)

Country Link
KR (1) KR20150063040A (pt)
BR (1) BR112015006642B1 (pt)
MX (1) MX2015003810A (pt)
PE (1) PE20151323A1 (pt)
PH (2) PH12015500353A1 (pt)
WO (1) WO2014048511A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103976970A (zh) * 2014-06-06 2014-08-13 程奉平 美他多辛缓释片的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301108C (zh) * 2004-10-15 2007-02-21 山东齐都药业有限公司 美他多辛分散片及其制备方法
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
KR101697773B1 (ko) * 2008-03-10 2017-01-18 유로드러그 레버러토리즈 비. 브이. 독소필린을 포함하는 변형 방출 조성물
IT1393338B1 (it) * 2009-03-06 2012-04-20 Baldacci Lab Spa Uso terapeutico della metadoxina come inibitore della fibrosi epatica.
EA023758B1 (ru) * 2009-06-25 2016-07-29 Алкобра Лтд. Применение метадоксина для лечения синдрома дефицита внимания/гиперактивности (adhd/add)
WO2011061743A1 (en) * 2009-11-18 2011-05-26 Alcobra Ltd. Metadoxine and derivatives thereof for use in the treatment of inflammation and immune-related disorders

Also Published As

Publication number Publication date
MX2015003810A (es) 2015-07-17
PE20151323A1 (es) 2015-10-10
PH12016501553B1 (en) 2017-09-11
BR112015006642B1 (pt) 2022-08-02
WO2014048511A1 (en) 2014-04-03
PH12015500353A1 (en) 2015-04-20
PH12016501553A1 (en) 2017-09-11
KR20150063040A (ko) 2015-06-08

Similar Documents

Publication Publication Date Title
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
CL2008003582A1 (es) Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).
BR112015008487A2 (pt) compostos de benzeno substituído
BR112012009214A2 (pt) compostos
BR112015008447A2 (pt) métodos para tratar câncer
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112014016810A2 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015001313A2 (pt) composições de vacina
BR112015018270A2 (pt) composições que compreendem 15-ohepa e métodos de uso das mesmas
MX2013003635A (es) Compuestos de n-heteroarilo.
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
BR112015006363A2 (pt) combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
MX370211B (es) Eteres de bis (hidroximetil) ciclohexanos.
HU0700024D0 (en) Use of enhancers in biglycan activuty in the preparation of pharmaceutical compositions having utility in cardiac diseases
BR112014016804A2 (pt) composições, métodos de uso e métodos de tratamento
BR112015006642A2 (pt) metadoxina, composição farmacêutica e composição farmacêutica de liberação prolongada
ES2446494B1 (es) Aplicación terapéutica de necrostatina-1 en esteatohepatitis

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/01/2013, OBSERVADAS AS CONDICOES LEGAIS